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Abstract 25 
Many of the nitroaromatic agents used in medicine function as prodrugs and must undergo 26 
activation before exerting their toxic effects. In most cases this is catalysed by FMN-27 
dependent type I nitroreductases (NTRs), a class of enzyme absent from higher eukaryotes 28 
but expressed by bacteria and several eukaryotic microbes including trypanosomes and 29 
Leishmania. Here, we utilize this difference to evaluate whether a library of aziridinyl 30 
nitrobenzamides have activity against Leishmania major. Biochemical screens using purified 31 
L. major NTR (LmNTR) revealed that compounds containing an aziridinyl-2,4-dinitrobenzyl 32 
core were effective substrates for the enzyme and showed that the 4-nitro group was 33 
important for this activity. To facilitate drug screening against intracellular amastigote 34 
parasites, we generated leishmanial cells that expressed the luciferase reporter gene and 35 
optimized a mammalian infection model in a 96-well plate format. A subset of aziridinyl-2,4-36 
dinitrobenzyl compounds possessing a 5-amide substituent displayed significant growth 37 
inhibitory properties against the parasite, with the most potent agents generating 50 % 38 
inhibitory concentrations of <100 nM towards the intracellular form. This antimicrobial 39 
activity was shown to be LmNTR specific since L. major NTR+/- heterozygote parasites were 40 
slightly resistance to the most aziridinyl dinitrobenzyl agents tested. When the most potent 41 
leishmanicidal agents were screened against the mammalian cells in which the amastigote 42 
parasites were propagated, no growth inhibitory effect was observed at concentration up to 43 
100 μM. We conclude that the aziridinyl nitrobenzamides represent a new lead structure that 44 
may have the potential to treat leishmanial infections. 45 
46 
3 
 
Introduction 47 
Leishmaniasis represents a series of insect transmitted, blood-borne diseases caused by 48 
more than 20 different protozoan parasite species belonging to the genus Leishmania. These 49 
infections are endemic throughout many tropical and sub-tropical countries where 350 50 
million people are at risk of infection (1). Estimates indicate that up to 12 million individuals 51 
are currently infected by these protozoan parasites, with up to 2 million new cases and 50,000 52 
deaths occurring each year (1). Recently, due to military activity, population migration, 53 
modern medical practices, intravenous drug usage and global warming the number of new 54 
cases in non-endemic areas has increased stimulating interest from pharmaceutical companies 55 
in these previously neglected infections (2-4). Drugs currently represent the only treatments 56 
available to combat leishmaniasis. For more than 60 years, front-line therapies have been 57 
based on pentavalent antimonial compounds but their use is problematic as they are toxic and 58 
require medical supervision to administer with clinical resistance now commonplace (5,6). In 59 
light of this worrying situation, a range of alternative treatments such as amphotericin B, 60 
paromomycin and miltefosine are now available but these too are far from ideal as they can 61 
be expensive and require medical administration, with some having teratogenic and other 62 
unwanted toxicity problems (7). Therefore, there is an urgent requirement for new, safer, cost 63 
effective anti-leishmanial treatments. 64 
Nitroaromatic compounds are used predominantly as broad spectrum antibiotics to treat 65 
various urinary and gastrointestinal tract infections. They are characterised by possessing at 66 
least one nitro group attached to an aromatic ring, that usually has a heterocyclic structure 67 
(e.g. imidazole, furan or thiazole) (8). However, following concerns over their safety, the use 68 
of many nitroaromatics has been  discontinued in Europe and USA although they are 69 
commonly prescribed elsewhere ((9-11); reviewed in (12)). It is now apparent that several 70 
nitro-based compounds are not as toxic as initially thought (13-15). Such observations have 71 
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stimulated renewed interested in this group of agents with calls made for the reinstatement of 72 
nitrofurantoin as a treatment for uncomplicated urinary tract infections, whilst several others 73 
have emerged as lead structures to treat various microbial infections and different forms of 74 
cancer, with fexinidazole and PA-824 undergoing evaluation to treat visceral leishmaniasis 75 
(16-24). 76 
Most nitroaromatic compounds used in medicine function as prodrugs and must undergo 77 
activation before mediating their therapeutic effects, reactions catalysed by nitroreductases 78 
(NTRs). Based on oxygen sensitivity, flavin cofactor and the reduction products, NTRs can 79 
be broadly divided into two classes, type I or type II NTRs (25). In many bacteria and 80 
eukaryotic microorganisms, FMN-containing type I NTRs use NAD(P)H to drive the 81 
sequential two electron reduction of the conserved nitro (-NO2) group to a hydroxylamine 82 
derivative (-NHOH) via an unstable nitroso intermediate (-NO) (see reactions 1 and 2). The 83 
hydroxylamine can be processed further to produce DNA damaging/crosslinking adducts and 84 
other toxic molecules such as open chain nitriles and reactive dialdehydes (18,25-32). 85 
Crucially, this reaction can occur in aerobic and anerobic environments indicating that the 86 
above reactions do not involve O2 and as such, FMN-type I catalysed activity is said to be 87 
“O2 insensitive”. For bacteria and trypanosomes, this mechanism of activation appears to be 88 
key for the selective toxicity of many nitroaromatic prodrugs as cells selected for resistance 89 
frequently show mutations in, or decreased expression of, their FMN-type I NTR gene 90 
complement (33-35). 91 
R-NO2 + 2e-  R-NO   (1) 92 
R-NO + 2e-  R-NHOH  (2) 93 
In contrast, the ubiquitous NAD(P)H dependent type II NTRs use FAD or FMN as a cofactor 94 
to catalyse the one electron reduction of the conserved nitro group to form an unstable nitro 95 
anion radical (-NO2•-). In the presence of O2, this radical can undergo futile cycling to 96 
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produce superoxide anions (O2-) and regenerate the parental compound (36,37) (see reactions 97 
3 and 4). Mammalian enzymes, such as NAD(P)H quinone oxidoreductase 1, can catalyse a 98 
two electron reduction reaction of many nitroaromatic prodrugs under aerobic conditions, 99 
however, mammalian nitroreduction does not utilise FMN containing -type I enzymes (38). 100 
R-NO2 + e-  R-NO2•-  (3) 101 
R-NO2•- + O2  R-NO2 + O2•- (4) 102 
Here, we exploit the activity of a FMN-type I NTR expressed by the protozoan parasite 103 
Leishmania major to conduct biochemical and phenotypic screens on a small library of 104 
azirindyl nitrobenzamide (ANB) compounds, agents we have previously shown to display 105 
significant anti-trypanosomal activities (39). Two of these compounds were highly active 106 
against intracellular form L major and displayed high selectivity toward the parasite. We 107 
postulate that compounds based around a 5-(aziridin-1-yl)-2,4-dinitrobenzamide core 108 
represent a promising new class of leishmanicidal agent. 109 
110 
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Materials and methods 111 
Chemicals 112 
Aziridinyl nitrobenzamides (ANB) structures are shown in Table 1. The synthesis of NH1-113 
8 is described elsewhere (40). CB1954 was purchased from Sigma Aldrich and NH9-12 were 114 
supplied by the Department of Therapeutics, NCI (USA). 115 
 116 
Cell culturing. 117 
L. major (MHOM/IL/80/Friedlin) promastigote parasites were grown at 27 oC in modified 118 
M199 medium (Life Technologies) (41). Transformed parasites were grown in this medium 119 
supplemented with G418 (20 μg mL-1 on agar plates, 40 μg mL-1 in broth) or blasticidin (10 120 
μg mL-1). L. major metacyclic form parasites were harvested from promastigote cultures as 121 
described (42). These were used to infect differentiated human acute monocytic leukemia 122 
(THP-1) cells at a ratio of 20 parasites per mammalian cell. The L. major-infected 123 
monolayers were incubated overnight at 37 oC under a 5 % (v/v) CO2 atmosphere in 124 
mammalian growth medium then washed with RPMI-1640 to remove residual parasites. L. 125 
major amastigote parasites were maintained in differentiated THP-1 cells at 37 oC under a 5 126 
% (v/v) CO2 atmosphere in RPMI-1640 medium. 127 
The human acute monocytic leukemia cell line (THP-1) was grown at 37 oC under a 5 % 128 
(v/v) CO2 atmosphere in RPMI-1640 medium (PAA Laboratories Ltd) supplemented with 2 129 
mM pyruvate, 2 mM sodium glutamate, 2.5 U mL-1 penicillin and 2.5 μg mL-1 streptomycin, 130 
20 mM HEPES pH 7.4 and 10% (v/v) foetal calf serum. Differentiation of THP-1 towards 131 
macrophage-like cells was carried out using phorbol 12-myristate 13-acetate (20 ng mL-1) 132 
(PMA) (Sigma-Aldrich) (43,44). 133 
 134 
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In vivo studies. 135 
All animal experiments were conducted under licence in accordance with UK Home 136 
Office regulations. L. major parasites were passaged through female BALB/c mice by 137 
subcutaneous injection of 2 × 107 purified metacyclic parasites in 100 μL RPMI medium 138 
without serum into the shaved rump. Amastigotes were harvested from skin lesions and 139 
allowed to transform back to promastigotes in 5 ml M199 medium.  140 
 141 
Anti-proliferative assays. 142 
All assays were performed in a 96-well plate format. L. major promastigote parasites (5 x 143 
105 mL-1) or differentiated THP-1 cells (2.5 x 104 mL-1) were seeded in 200 μl growth 144 
medium containing different concentrations of nitroaromatic agent. After incubation at 27 oC 145 
for 5 days (L. major) or at 37 oC for 3 days (THP-1), 2.5 μg resazurin (20 μL of 0.125 μg mL-146 
1 stock in phosphate buffered saline) was added to each well and the plates incubated for a 147 
further 8-16 hours. Cell densities were determined by monitoring the fluorescence of each 148 
culture using a Gemini Fluorescent Plate Reader (Molecular Devices (UK) Ltd, Wokingham, 149 
UK) at an excitation wavelength of 530 nm, emission wavelength of 585 nm and a filter cut 150 
off at 550 nm, and the drug concentration that inhibits cell growth by 50 % (IC50) established. 151 
Growth inhibition of luciferase expressing L. major amastigotes was monitored as follows. 152 
THP-1 cells seeded at 2.5 x 104 mL-1 in 200 μl in growth medium containing PMA (20 ng 153 
mL-1) were incubated at 37 oC in a 5 % (v/v) CO2 atmosphere for 3 days. Macrophage 154 
monolayers were washed with mammalian growth medium then infected with purified 155 
luciferase expressing L. major metacyclic cells (5 x 105 cells mL-1) resuspended in 200 μL 156 
mammalian growth medium. Following incubation overnight at 37 °C in a 5 % (v/v) CO2 157 
atmosphere, the cultures were washed twice in growth medium to remove non-internalised 158 
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parasites and the supernatant replaced with fresh growth medium containing the compound 159 
under investigation. Compound treated infections were incubated for a further 3 days at 37 oC 160 
under a 5 % (v/v) CO2. The growth medium was then removed and the cells lysed in 50 μL 161 
cell culture lysis reagent (Promega). Activity was then measured using the luciferase assay 162 
system (Promega) and light emission measured on a ß-plate counter (Perkin Elmer). The 163 
luminescence is proportional to the number of live cells. The IC50 value for each compound 164 
was then established. 165 
 166 
Plasmids and parasite genetic manipulation. 167 
DNA fragments corresponding to the L. major 5’ rRNA spacer/promoter and 3’ spacer 168 
rRNA regions were amplified from L. major Friedlin genomic DNA and sequentially cloned 169 
into the Trypanosoma cruzi vector pTRIX-Luc (39) replacing the equivalent T. cruzi 5’ rRNA 170 
spacer/promoter and 3’ spacer rRNA sequences. A polypyrimidine tract/spliced leader 171 
addition site sequence located upstream the T. cruzi MPX gene was then isolated and inserted 172 
between the L. major 5’ rRNA spacer/promoter region and luciferase reporter to form the 173 
integrative vector pLmRIX-Luc. Following linearization, this DNA was introduced into L. 174 
major promastigotes in the logarithmic phase of growth using the Human T-cell 175 
Nucleofector® kit and an Amaxa® Nucleofector™ (Lonza AG) set to program U-033. 176 
A DNA fragment encoding for the catalytic domain of L. major NTR (LmNTR) was 177 
amplified from genomic DNA with the primers ggatccCTCGACGCCGTCGAGGCCGTCG 178 
and gaattcCTAGAACTTGTTCCACCGCAC; lower-case italics correspond to restriction 179 
sites incorporated into the primers to facilitate cloning. The fragment was digested with 180 
BamHI/HindIII then cloned into the corresponding sites of the vector pTrcHis-C (Invitrogen) 181 
to form the plasmid pTrcHisC-LmNTR. 182 
 183 
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Enzyme assay.  184 
Recombinant HIS-tagged LmNTR was purified as described (45). Type I NTR activity was 185 
measured spectrophotometrically by monitoring the formation of the 2- and 4-hydroxylamine 186 
derivatives from the parent ANB (λ = 420 nm, ε = 1,220 M-1 cm-1) (46). A standard reaction 187 
(1 mL) containing 50 mM Tris-Cl pH7.5, 100 µM NADH and 100 µM electron acceptor was 188 
incubated at room temperature for 5 min. The background reaction rate was determined and 189 
the assay initiated by addition of the LmNTR (35 µg). For nifurtimox, activity was measured 190 
spectrophotometrically by monitoring reduction of this compound (λ = 435 nm, ε = 19,000 191 
M-1 cm-1) (47). Enzyme activities were expressed in nmoles of NADH oxidised per minute 192 
per mg LmNTR and assumes that four NADH molecules are oxidised per molecule of ANB 193 
or nifurtimox reduced (46, 47). 194 
195 
10 
 
Results 196 
Construction and evaluation of luciferase expressing Leishmania major  197 
Several drug screening systems are now in place for use with Leishmania, each having 198 
their own advantages and disadvantages. To facilitate screening of nitroaromatic compounds, 199 
which are often coloured, we developed a L. major line that constitutively expresses 200 
luciferase. The integrative vector pLmRIX-Luc was generated by sequentially cloning DNA 201 
fragments containing the 5' and 3' L. major Friedlin rRNA promoter/spacer sequences either 202 
side of an expression cassette derived from pTEX containing the luciferase and neomycin 203 
phosphotransferase genes (39). To assist luciferase mRNA processing, an untranslated 204 
sequence corresponding to the T. cruzi mitochondrial peroxiredoxin gene polypyrimidine 205 
tract/spliced leader addition site was then inserted between the 5' L. major rRNA region and 206 
reporter gene. The DNA fragment containing L. major rRNA/luciferase/neomycin 207 
phosphotransferase sequences was then purified following restriction digestion and 208 
electroporated into promastigote form parasites. After selection with G418, the luciferase 209 
activity from several clones was determined and shown to be up to 1,000-fold higher than 210 
that of the parental line (Fig. 1A). The effect of luciferase expression on various L. major life 211 
cycle stages was then evaluated. This showed that the reporter did not influence: (i) growth of 212 
promastigote parasites, (ii) the ability of promastigote cells to differentiate into infective 213 
metacyclic forms, (iii) invasion of tissue culture derived macrophages by metacyclics, or (iv) 214 
growth of intracellular amastigote parasites (Fig. 1B and E) . Additionally the luciferase 215 
expressing parasites were passaged through BALB/c mice and amastigote recovered from 216 
infected animals could readily differentiate to the promastigote form and be grown in culture. 217 
Therefore, it is implicit that luciferase expression has no effect on L. major growth, 218 
differentiation, and infectivity. 219 
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A prerequisite for any drug screening assay requires that reporter levels provide an 220 
accurate representation of cell number. Using extracts derived from serially diluted 221 
promastigotes, a linear relationship between luciferase activity and parasite load was 222 
observed over the range of 625 to 160,000 cells (Fig. 1C). In the case of amastigotes such a 223 
correlation was shown by evaluating reporter levels in lysates from a fixed number of 224 
macrophages infected for 16-20 h with varying L. major loads (Fig. 1D): luciferase activity 225 
was linear when using a parasite:mammalian cell ratio of 2.5-80:1. With this established the 226 
luciferase expressing cells were then appraised as to whether they could be used for in vitro 227 
drug screens in a 96-well plate format using nifurtimox as the reference compound. For 228 
promastigote assays, cells were grown in the presence of different concentrations of the 229 
nitrofuran for 6 days and the extracts tested for luminescence activity (Fig. 2A). From the 230 
resultant dose response curves nifurtimox exhibited an IC50 value of 7.50 ± 0.40 μM, in line 231 
with the IC50 value (6.30 ± 0.10 μM) obtained when using the fluorescent vital dye resazurin. 232 
For the intracellular amastigote assays, differentiated THP-1 cells were infected with 233 
recombinant L. major at a ratio of 20 parasites per mammalian cell. Following 72 hours 234 
growth post-infection in the presence of drug, the luciferase activity for each culture 235 
determined from which dose response curves were generated (Fig. 2B). From these plots, the 236 
IC50 value for nifurtimox was calculated to be 0.58 ± 0.06 μM. When the susceptibility of 237 
differentiated THP-1 cells to nifurtimox was determined using resazurin, the IC50 value was 238 
calculated to be >100 μM (Table 2) demonstrating that this nitrofuran has a selective toxicity 239 
of >170 toward the intracellular parasite. Therefore, based on our data, nifurtimox shows 240 
selective killing of the L. major amastigotes and the observed leishmanicidal activity is not 241 
due to death of the mammalian cell. 242 
243 
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Metabolism of nitrobenzamides by the leishmanial NTR. 244 
Many nitroaromatic prodrugs undergo activation in reactions catalysed by FMN-type I 245 
NTRs. Here, we evaluated whether CB1954 and twelve related ANBs could function as 246 
substrates for purified HIS-tagged L. major NTR using NADH as an electron donor (Fig. 3). 247 
Normally, assays involving this parasite enzyme can be readily followed by monitoring the 248 
change in absorbance at 340 nm, corresponding to the oxidation of NADH. However, many 249 
ANBs undergo a considerable change in absorbance at this particular wavelength. Instead, 250 
enzyme activity was assayed by monitoring the change in absorbance at 420 nm which 251 
corresponds to the appearance of the hydroxylamine metabolite (46). 252 
Of the thirteen compounds screened, most (ten) were metabolised by LmNTR at a rate 253 
faster than that noted for nifurtimox. These “active” compounds were related in that they all 254 
contain two nitro groups at positions 2- and 4- relative to the 1-aziridinyl ring. In contrast, the 255 
three ANBs that contain a single 2-nitro group were deemed “poor” substrates for the parasite 256 
enzyme, having negligible activity values. 257 
 258 
Leishmanicidal activity and mammalian cytotoxicity of aziridinyl nitrobenzamides. 259 
To determine whether there was a correlation between LmNTR activity and anti-260 
leishmanial activity, all compounds were screened against L. major promastigotes and 261 
luciferase expressing amastigotes. Initial tests using a fixed concentration of compound (10 262 
μM) were set up to evaluate the growth inhibitory properties of the ANB series. Out of the 263 
thirteen compounds tested, five had no effect on either parasite stage at this concentration 264 
(Table 2) while two others had no effect on promastigote cells but did have activity against 265 
intracellular form L. major. Three of the five compounds that have no effect against 266 
promastigote and amastigote parasites correspond to the ANBs previously identified as 267 
“poor” LmNTR substrates. To evaluate the growth inhibitory activities of those structures 268 
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identified by the initial screen, a series of secondary assays were performed using various 269 
concentrations of the ANB. For each agent dose response curves were drawn from which the 270 
compound’s IC50 was determined (Table 2) (Fig. 4). Out of the six compounds tested against 271 
promastigotes, CB1954, NH10 and NH11 had IC50 values <1 μM. These, plus NH9, also 272 
displayed sub-micromolar IC50’s against amastigote parasites with two (CB1964 and NH11) 273 
yielding values <100 nM. All compounds that display leishmanicidal activity against either of 274 
the L. major forms were assayed for cytotoxicity against differentiated THP-1 cells (Table 2) 275 
(Fig. 4). In all cases, the ANBs screened had no growth inhibitory effect against this 276 
mammalian line at concentrations up to 100 μM. Comparison of the mammalian cell IC50 277 
with the equivalent value obtained against amastigote parasites revealed that CB1964 and 278 
NH11 displayed >2000 and >1667-fold selective toxicity toward the intracellular pathogen, 279 
respectively. This clearly demonstrates that the anti-parasitic activity displayed by these two 280 
compounds was specifically due to growth inhibition of L. major and not due to induction of 281 
host cell toxicity. 282 
To demonstrate that LmNTR played a role in prodrug activiation in the parasite itself, the 283 
susceptibility of LmNTR+/- heterozygous promastigotes to CB1954, NH10 and NH11 was 284 
evaluated: attempts (16 independent transformations) to generate L. major LmNTR-/- null 285 
mutants failed to produce recombinant cells leading us to speculate that this activity is 286 
essential in insect stage parasites (48). This screening demonstrated that cells expressing 287 
lower levels of the oxidoreductase were between 2- and 4-fold more resistant to the ANB 288 
than controls: wild type L. major had IC50 values of 0.42 ± 0.01 μM, 0.49 ± 0.04 μM and 289 
0.91 ± 0.07 μM against CB1954, NH10 and NH11, respectively, while LmNTR+/- 290 
heterozygotes displayed IC50 values of 1.62 ± 0.02 μM, 1.00 ± 0.07 μM and 1.77 ± 0.01 μM 291 
towards these agents. 292 
293 
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Discussion 294 
Several high throughput phenotypic screening approaches are now available to facilitate 295 
the search for novel drugs targeting the medically relevant, intracellular stage of Leishmania. 296 
Of these, the luciferase-based systems have proven to be sensitive, rapid, reproducible and 297 
versatile with tagged parasites now being used to follow the fate of the pathogen during the 298 
course of an animal model infection (49-52). Here, we constructed a luciferase expressing L. 299 
major line making use of an existing T. cruzi integration vector, modifying the expression 300 
construct such that it would integrate into the leishmanial ribosomal array (39). 301 
Characterisation of the recombinant line established that expression of the reporter had no 302 
effect on L. major promastigote growth, metacyclogenesis and proliferation of the 303 
intracellular amastigote form. Using luciferase expressing L. major, growth inhibition assays 304 
were established with nifurtimox employed as selective compound for promastigote or 305 
amastigote cells in a standardized 96-well plate format. 306 
Nitrobenzamide-based compounds that contain an aziridinyl ring or mustard substituent 307 
have been evaluated as potential therapies targeting hypoxic cancers and the trypanosomal 308 
infections African sleeping sickness and Chagas’ disease (53-55). These structures invariably 309 
function as prodrugs with their toxicity dependent on reduction of the nitro group(s) to its 310 
hydroxylamine derivatives, reactions catalysed by FMN-type I NTRs (18,21). This 311 
bioreductive trigger promotes an electronic reconfiguration on the compound’s aromatic ring 312 
leading to presentation of cytotoxic moieties to the cell (55). For the treatment of hypoxic 313 
cancers, the FMN-type I NTR activity must be introduced into mammalian cells using gene- 314 
or antibody-based approaches before addition of the nitrobenzamide whereas in 315 
trypanosomes an essential endogenous enzyme can be exploited to catalyse the above nitro 316 
reduction (18,21,55). As Leishmania also express a FMN-type I NTR, it is postulated that 317 
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nitroaromatic compounds may have potential for the treatment of various forms of 318 
leishmaniasis (24). 319 
Following the identification that CB1954, the archetypal ANB, displayed potent anti-320 
tumor activity against the Walker 256 carcinoma, a series of derivatives have been 321 
synthesised differing in the number/location of nitro groups and other substituents attached to 322 
a central benzyl ring core (40,56). Using a small library (14 compounds) of these structures in 323 
biochemical screens, we demonstrated that compounds having two nitro groups located at the 324 
2- and 4- positions on an aromatic ring backbone relative to the aziridinyl ring were readily 325 
metabolised by LmNTR. The location of an amide (or amine)-containing substituent at the 5- 326 
(group Ia) or 6- (group II) position did not affect this in vitro activity. In contrast, 327 
replacement of the 4-nitro group with an H or SO2Me substituent (group Ib) generated 328 
compounds that were not metabolized by LmNTR. These biochemical studies revealed that 329 
LmNTR exhibits a slightly different substrate preference compared to Trypanosoma brucei 330 
NTR (TbNTR). In contrast to LmNTR the trypanosomal enzyme was only able to metabolise 331 
compounds having the group Ia configuration. This highlights the importance of the 4-nitro 332 
group during prodrug activation with both LmNTR and TbNTR unable to metabolise 333 
compounds with a group Ib arrangement (39). 334 
When tested against Leishmania, all group Ia structures showed potent growth inhibitory 335 
properties toward promastigote and/or amastigote parasites thus mirroring the biochemical 336 
observations. Several of these ANBs yielded IC50’s below 1 μM against the intracellular L. 337 
major, including CB1954 and NH11 that had sub 100 nM values. In contrast, none of the 338 
group Ib ANBs had an effect on parasite growth, consistent with observations made using the 339 
trypanosomal NTRs and mammalian cells expressing E. coli FMN-type I NTRs, again 340 
highlighting the importance of the 4-nitro group and its reduction products make in mediating 341 
cytotoxicity (39,40,57). Surprisingly, of the group II compounds only NH6 displayed any 342 
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leishmanicidal activity. NH6 had a lower potency compared with its structural isomer 343 
CB1954 (CB1954 was 42- and 16-fold more effective at inhibiting amastigote and 344 
promastigote parasite growth than NH6, respectively). The decreased potency displayed by 345 
group II compounds may reflect the ability of these structures (or their reduction products) to 346 
access regions of the cell where activation (or downstream leishmanicidal processes) take 347 
place. This could be in part due to the spatial arrangement of these substituents (located at the 348 
6- position on the benzyl ring) which may hinder the presentation of the adjacent azirindinyl 349 
cytotoxic moiety to biomolecular targets within the cellular environment. 350 
To conclusively demonstrate the link between LmNTR and leishmanicidal activities, the 351 
susceptibility of L. major LmNTR+/- heterozygous cell line to the most effective compounds 352 
(CB1954, NH10 and NH11) was investigated (49). In this context, parasites with lower levels 353 
of NTR displayed relative resistance to all compounds tested, mirroring observations made 354 
for the trypanocidal, NTR-activated nitroaromatic prodrugs (35,39,45,47). This, in 355 
conjunction with the observation that none of the group Ia compounds displayed cytotoxicity 356 
to the macrophage-like cells within which the intracellular L. major were cultured, suggests 357 
that the group Ia ANBs specifically target the parasite itself rather than by promoting death to 358 
the mammalian cell.  359 
We have now identified two leishmanidical ANB-based compounds (CB1954 and NH11) 360 
that display significant potency toward the L. major forms that replicate inside the 361 
mammalian host. These structures were shown to mediate their anti-parasitic activities 362 
following specific activation in a reaction catalysed by a FMN-type I NTR, an activity 363 
present in the pathogen but absent from the mammalian macrophage cells. Indeed these 364 
compounds display little or no cytotoxicity to the mammalian macrophage-like cell having 365 
>1660-fold selectivity when targeting intracellular parasites although when using in vivo 366 
rodent models CB1954 does exhibit hepatotoxicity, neurotoxicity and causes gastrointestinal 367 
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tract disturbances (58, 59): the toxicity/pharmacokinetics of other ANBs screened here have 368 
not been determined. Despite this group Ia compounds, particularly CB1954 and NH11, 369 
warrant further attention in the development of novel leishmanidical therapies and ideally 370 
represent one component of a new combinatorial treatment. 371 
   372 
Acknowledgments 373 
Andrew Voak was a recipient of a Queen Mary University of London Graduate Training 374 
Studentship 375 
 376 
References 377 
1. Stuart, K., R. Brun, S. Croft, A. Fairlamb, R. E. Gurtler, J. McKerrow, S. Reed, 378 
and R. Tarleton. 2008. Kinetoplastids: related protozoan pathogens, different 379 
diseases. J. Clin. Invest. 118: 1301-1310. 380 
2. Cruz, I., C. Canavate, J. M. Rubio, M.A. Morales, C. Chicharro, F. Laguna, M. 381 
Jimenez-Mejias, G. Sirera, S. Videla, and J. Alvar. 2002. Leishmania in discarded 382 
syringes from intravenous drug users. Trans. R. Soc. Trop. Med. Hyg. 96 Suppl 1: 383 
S185-189. 384 
3. Gonzalez, C., O. Wang, S. E. Strutz, C. Gonzalez-Salazar, V. Sanchez-Cordero, 385 
and S. Sarkar. 2010. Climate change and risk of leishmaniasis in North America: 386 
predictions from ecological niche models of vector and reservoir species. PLoS Negl. 387 
Trop. Dis. 4: e585. 388 
4. Pavli, A., and H.C. Maltezou. 2010. Leishmaniasis, an emerging infection in 389 
travelers. Int. J. Infect. Dis. 14: e1032-1039. 390 
5. Croft, S. L., S. Sundar, and A. H. Fairlamb. 2006. Drug resistance in leishmaniasis. 391 
Clin. Microbiol. Rev. 19: 111-126. 392 
6. Haldar, A.K., P. Sen, and S. Roy. 2011. Use of antimony in the treatment of 393 
leishmaniasis: current status and future directions. Mol. Biol. Int. 2011, 571242. 394 
7. Croft, S. L., and P. Olliaro. 2011. Leishmaniasis chemotherapy - challenges and 395 
opportunities. Clin. Microbiol. Infect. 17: 1478-1483. 396 
8. Grunberg, E., and E. H. Titsworth. 1973. Chemotherapeutic properties of 397 
heterocyclic compounds: monocyclic compounds with five-membered rings. Annu. 398 
Rev. Microbiol. 27: 317-346. 399 
9. Takahashi, M., S. Iizuka, T. Watanabe, M. Yoshida, J. Ando, K. Wakabayashi, 400 
and A. Maekawa. 2000. Possible mechanisms underlying mammary carcinogenesis 401 
in female Wistar rats by nitrofurazone. Cancer Lett. 156: 177-184. 402 
10. Padda, R. S., C. Wang, J. B. Hughes, R. Kutty, and G. N. Bennett. 2003. 403 
Mutagenicity of nitroaromatic degradation compounds. Environ. Toxicol. Chem. 22: 404 
2293-2297. 405 
18 
 
11. Hiraku, Y., A. Sekine, H. Nabeshi, K. Midorikawa, M. Murata, Y. Kumagai, and 406 
S. Kawanishi. 2004. Mechanism of carcinogenesis induced by a veterinary 407 
antimicrobial drug, nitrofurazone, via oxidative DNA damage and cell proliferation. 408 
Cancer Lett. 215: 141-150. 409 
12. McCalla, D. R. 1983. Mutagenicity of nitrofuran derivatives: review. Environ. 410 
Mutagen. 5: 745-765. 411 
13. Matsumoto, M., H. Hashizume, T. Tomishige, M. Kawasaki, H. Tsubouchi, H. 412 
Sasaki, Y. Shimokawa, and M. Komatsu. 2006. OPC-67683, a nitro-dihydro-413 
imidazooxazole derivative with promising action against tuberculosis in vitro and in 414 
mice. PLoS Med. 3: e466. 415 
14. Tweats, D., B. Bourdin Trunz, and E. Torreele. 2012. Genotoxicity profile of 416 
fexinidazole - a drug candidate in clinical development for human African 417 
trypanomiasis (sleeping sickness). Mutagenesis 27: 523-532. 418 
15. Trunz, B. B., R. Jedrysiak, D. Tweats, R. Brun, M. Kaiser, J. Suwinski, and E. 419 
Torreele. 2011. 1-Aryl-4-nitro-1H-imidazoles, a new promising series for the 420 
treatment of human African trypanosomiasis. Eur. J. Med. Chem. 46: 1524-1535. 421 
16. Stover, C. K., P. Warrener, D. R. VanDevanter, D. R. Sherman, T. M. Arain, M. 422 
H. Langhorne, S. W. Anderson, J. A. Towell, Y. Yuan, D. N. McMurray, B. N. 423 
Kreiswirth, C. E. Barry, and W. R. Baker. 2000. A small-molecule 424 
nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405: 962-425 
966. 426 
17. Adagu, I. S., D. Nolder, D. C. Warhurst, and J. F. Rossignol. 2002. In vitro 427 
activity of nitazoxanide and related compounds against isolates of Giardia 428 
intestinalis, Entamoeba histolytica and Trichomonas vaginalis. J. Antimicrob. 429 
Chemother. 49: 103-111. 430 
18. Denny, W. A. 2003. Prodrugs for Gene-Directed Enzyme-Prodrug Therapy (Suicide 431 
Gene Therapy). J. Biomed. Biotechnol. 2003: 48-70. 432 
19. Korba, B. E., A. B. Montero, K. Farrar, K. Gaye, S. Mukerjee, M. S. Ayers, and 433 
J. F. Rossignol. 2008. Nitazoxanide, tizoxanide and other thiazolides are potent 434 
inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral. Res. 77: 56-435 
63. 436 
20. Arya, S. C., and N. Agarwal. 2009. Nitrofurantoin: the return of an old friend in the 437 
wake of growing resistance. BJU Int. 103: 994-995. 438 
21. Chen, Y., and L. Hu. 2009. Design of anticancer prodrugs for reductive 439 
activation.Med. Res. Rev. 29, 29-64. 440 
22. Torreele, E., B. Bourdin Trunz, D. Tweats, M. Kaiser, R. Brun, G. Mazue, M. A. 441 
Bray, and B. Pecoul. 2010. Fexinidazole-a new oral nitroimidazole drug candidate 442 
entering clinical development for the treatment of sleeping sickness. PLoS Negl. 443 
Trop. Dis. 4: e923. 444 
23. Wyllie, S., S. Patterson, L. Stojanovski, F. R. Simeons, S. Norval, R. Kime, K. D. 445 
Read, and A. H. Fairlamb. 2012. The anti-trypanosome drug fexinidazole shows 446 
potential for treating visceral leishmaniasis. Sci. Transl. Med. 4: 119re111. 447 
24. Patterson, S., S. Wyllie, L. Stojanovski, M. R. Perry, F. R. Simeons, S. Norval, 448 
M. Osuna-Cabello, M. De Rycker, K. D. Read, and A. H. Fairlamb. 2013 The R 449 
enantiomer of the anti-tubercular drug PA-824 as a potential oral treatment for 450 
visceral leishmaniasis. Antimicrob. Agents. Chemother. in press. 451 
doi:10.1128/AAC.00722-13 452 
19 
 
25. Peterson, F. J., R. P. Mason, J. Hovsepian, and J. L. Holtzman. 1979. Oxygen-453 
sensitive and -insensitive nitroreduction by Escherichia coli and rat hepatic 454 
microsomes. J. Biol. Chem. 254: 4009-4014. 455 
26. Gavin, J. J., F. F. Ebetino, R. Freedman, and W. E. Waterbury. 1966. The aerobic 456 
degradation of 1-(5-nitrofurfurylideneamino)-2-imidazolidinone (NF-246) by 457 
Escherichia coli. Arch. Biochem. Biophys. 113: 399-404. 458 
27. McCalla, D. R., A. Reuvers, and C. Kaiser. 1971. Breakage of bacterial DNA by 459 
nitrofuran derivatives. Cancer Res. 31, 2184-2188. 460 
28. Whitmore, G. F., A. J. Varghese, and S. Gulyas. 1986. Reaction of 2-461 
nitroimidazole metabolites with guanine and possible biological consequences. IARC 462 
Sci. Publ., 185-196. 463 
29. Whitmore, G. F., and A. J. Varghese. 1986. The biological properties of reduced 464 
nitroheterocyclics and possible underlying biochemical mechanisms. Biochem. 465 
Pharmacol. 35: 97-103. 466 
30. Streeter, A. J., and B. A. Hoener. 1988. Evidence for the involvement of a nitrenium 467 
ion in the covalent binding of nitrofurazone to DNA. Pharm. Res. 5: 434-436. 468 
31. Hall, B. S., C. Bot, and S. R. Wilkinson. 2011. Nifurtimox activation by 469 
trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites. J. Biol. 470 
Chem. 286: 13088-13095. 471 
32. Hall, B. S., and S.R. Wilkinson. 2012. Activation of benznidazole by trypanosomal 472 
type I nitroreductases results in glyoxal formation. Antimicrob. Agents. Chemother. 473 
56: 115-123. 474 
33. McCalla, D. R., C. Kaiser, and M. H. Green. 1978. Genetics of nitrofurazone 475 
resistance in Escherichia coli. J. Bacteriol. 133: 10-16. 476 
34. Whiteway, J., P. Koziarz, J. Veall, N. Sandhu, P. Kumar, B. Hoecher, and I. B. 477 
Lambert. 1998. Oxygen-insensitive nitroreductases: analysis of the roles of nfsA and 478 
nfsB in development of resistance to 5-nitrofuran derivatives in Escherichia coli. J. 479 
Bacteriol. 180: 5529-5539. 480 
35. Wilkinson, S. R., M. C. Taylor, D. Horn, J. M. Kelly, and I. Cheeseman. 2008. A 481 
mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. 482 
Proc. Natl. Acad. Sci. USA 105: 5022-5027. 483 
36. Moreno, S. N., R. P. Mason, R. P. Muniz, F. S. Cruz, and R. Docampo. 1983. 484 
Generation of free radicals from metronidazole and other nitroimidazoles by 485 
Tritrichomonas foetus. J. Biol. Chem. 258: 4051-4054. 486 
37. Moreno, S. N., R. P. Mason, and R. Docampo. 1984. Reduction of nifurtimox and 487 
nitrofurantoin to free radical metabolites by rat liver mitochondria. Evidence of an 488 
outer membrane-located nitroreductase. J. Biol. Chem. 259: 6298-6305. 489 
38. Chen, S., R. Knox, K. Wu, P. S. Deng, D. Zhou, M. A. Bianchet, and L. M. 490 
Amzel. 1997. Molecular basis of the catalytic differences among DT-diaphorase of 491 
human, rat, and mouse. J. Biol. Chem. 272: 1437-1439. 492 
39. Bot, C., B. S. Hall, N. Bashir, M. C. Taylor, N. A. Helsby, and S. R. Wilkinson. 493 
2010. Trypanocidal activity of aziridinyl nitrobenzamide prodrugs. Antimicrob. 494 
Agents Chemother. 54: 4246-4252. 495 
40. Helsby, N. A., G. J.Atwell, S. Yang,  B. D. Palmer, R. F. Anderson, S. M. Pullen, 496 
D. M. Ferry, A. Hogg, W. R. Wilson, and W. A. Denny. 2004. 497 
Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for 498 
activation by E. coli nitroreductase. J. Med. Chem. 47: 3295-3307. 499 
20 
 
41.  Kapler, G. M., C. M. Coburn, and S. M. Beverley. 1990. Stable transfection of the 500 
human parasite Leishmania major delineates a 30-kilobase region sufficient for 501 
extrachromosomal replication and expression. Mol. Cell. Biol. 10:1084-1094. 502 
42. da Silva, R., and D. L. Sacks. 1987. Metacyclogenesis is a major determinant of 503 
Leishmania promastigote virulence and attenuation. Infect. Immun. 55: 2802-2806. 504 
43. Fleit, H. B., and C. D. Kobasiuk. 1991. The human monocyte-like cell line THP-1 505 
expresses Fc gamma RI and Fc gamma RII. J. Leukoc. Biol. 49: 556-565. 506 
44. Tsuchiya, S., M. Yamabe, Y. Yamaguchi, Y. Kobayashi, T. Konno, and K. Tada. 507 
1980. Establishment and characterization of a human acute monocytic leukemia cell 508 
line (THP-1). Int. J. Cancer 26: 171-176. 509 
45  Hall, B. S., X. Wu, L. Hu, and S. R. Wilkinson. 2010. Exploiting the drug-510 
activating properties of a novel trypanosomal nitroreductase. Antimicrob. Agents 511 
Chemother. 54: 1193-1199. 512 
46. Race, P. R., A. L. Lovering, S. A.White, J. I. Grove, P. F. Searle, C. W. 513 
Wrighton, and E. I. Hyde. 2007. Kinetic and structural characterisation of 514 
Escherichia coli nitroreductase mutants showing improved efficacy for the prodrug 515 
substrate CB1954. J. Mol. Biol. 368: 481-492. 516 
47. Bot, C., B. S. Hall, G. Alvarez, R. Di Maio, M. Gonzalez, H. Cerecetto, and S. R. 517 
Wilkinson. 2013. Evaluating 5-nitrofurans as trypanocidal agents. Antimicrob. 518 
Agents Chemother. 57: 1638-1647. 519 
48. Voak, A. A., V. Gobalakrishnapilla, K. Seifert, E. Balczo, L. Hu, B. S. Hall, and 520 
S. R. Wilkinson. 2013. An essential type I nitroreductase from Leishmania major can 521 
be used to activate leishmanicidal prodrugs. J. Biol. Chem. in press. doi: 522 
10.1074/jbc.M113.494781  523 
49. de La Llave, E., H. Lecoeur, A. Besse, G. Milon, E. Prina, and T. Lang. 2011. A 524 
combined luciferase imaging and reverse transcription polymerase chain reaction 525 
assay for the study of Leishmania amastigote burden and correlated mouse tissue 526 
transcript fluctuations. Cell. Microbiol. 13: 81-91. 527 
50. Michel, G., B. Ferrua, T. Lang, M. P. Maddugoda, P. Munro, C. Pomares, E. 528 
Lemichez, and P. Marty. 2011. Luciferase-expressing Leishmania infantum allows 529 
the monitoring of amastigote population size, in vivo, ex vivo and in vitro. PLoS Negl. 530 
Trop. Dis. 5: e1323. 531 
51. Thalhofer, C. J., J. W. Graff, L. Love-Homan, S. M. Hickerson, N. Craft, S. M. 532 
Beverley, and M. E. Wilson. 2010. In vivo imaging of transgenic Leishmania 533 
parasites in a live host. J. Vis Exp.  534 
52. Roy, G., C. Dumas, D. Sereno, Y. Wu, A. K. Singh, M. J. Tremblay, M. 535 
Ouellette, M. Olivier, and B. Papadopoulou. 2000. Episomal and stable expression 536 
of the luciferase reporter gene for quantifying Leishmania spp. infections in 537 
macrophages and in animal models. Mol. Biochem. Parasitol. 110: 195-206. 538 
53. Jameson, M. B., D. Rischin, M. Pegram, J. Gutheil, A. V. Patterson, W. A. 539 
Denny, and W. R. Wilson. 2010. A phase I trial of PR-104, a nitrogen mustard 540 
prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid 541 
tumors. Cancer Chemother. Pharmacol. 65: 791-801. 542 
54. Patel, P., J. G. Young, V. Mautner, D. Ashdown, S. Bonney, R. G. Pineda, S. I. 543 
Collins, P. F. Searle, D. Hull, E. Peers, J. Chester, D. M. Wallace, A. Doherty, H. 544 
Leung, L. S. Young, and N. D. James. 2009. A phase I/II clinical trial in localized 545 
prostate cancer of an adenovirus expressing nitroreductase with CB1954. Mol. Ther. 546 
17: 1292-1299. 547 
21 
 
55. Wilkinson, S. R., C. Bot, J. M. Kelly, and B. S. Hall. 2011. Trypanocidal activity of 548 
nitroaromatic prodrugs: current treatments and future perspectives. Curr. Top. Med. 549 
Chem. 11: 2072-2084. 550 
56. Cobb, L. M., T. A. Connors, L. A. Elson, A. H. Khan, B. C. Mitchley, W. C. Ross, 551 
and M. E. Whisson. 1969. 2,4-dinitro-5-ethyleneiminobenzamide (CB 1954): a 552 
potent and selective inhibitor of the growth of the Walker carcinoma 256. Biochem. 553 
Pharmacol. 18: 1519-1527. 554 
57. Helsby, N. A., D. M. Ferry, A. V. Patterson, S. M. Pullen, and W. R. Wilson. 555 
2004. 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander 556 
effects in nitroreductase GDEPT. Br. J. Cancer 90: 1084-1092. 557 
58. Chung-Faye, G., D. Palmer, D. Anderson, J. Clark, M. Downes, J. Baddeley, S. 558 
Hussain, P. I. Murray, P. Searle,  L. Seymour, P. A. Harris, D. Ferry, and D. J. 559 
Kerr. 2001. Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a 560 
phase I and pharmacokinetic study of its prodrug, CB 1954. Clin. Cancer Res. 7: 561 
2662–266 562 
59. Tang, M.H., N. A. Helsby, M. A. Goldthorpe, K. M. Thompson, S. Al-Ali, and M. 563 
D. Tingle. 2007. Hepatic nitroreduction, toxicity and toxicokinetics of the anti-tumour 564 
prodrug CB 1954 in mouse and rat. Toxicology. 240: 70-85. 565 
 566 
22 
 
Tables 567 
Table 1: Structure of aziridinyl nitrobenzamide compounds. 568 
 
O2N
N
R1
R2
R3
 
 
Compound Group Structure 
CB1954 Ia R1=NO2; R2=CONH2; R3=H 
NH1 Ia R1=NO2; R2=CONH(CH2)2Nmorpholide; R3=H  
NH2 Ia R1=NO2; R2=CONH(CH2)2CO2Me; R3=H  
NH9 Ia R1= NO2; R2=oxazole; R3=H 
NH10 Ia R1=NO2; R2=CONHCH2CHCH2; R3=H 
NH11 Ia R1=NO2; R2=CONH(CH3)CH3; R3=H 
NH12 Ia R1=NO2; R2=R3=H 
 
NH3 
 
Ib 
 
R1=H; R2= R2=CONH2; R3=H 
NH4 Ib R1= SO2Me; R2= CONH2; R3=H 
NH5 Ib R1=SO2Me; R2= NHCH2CH(OH)CH2OH; R3=H 
 
NH6 
 
II 
 
R1= NO2; R2=H; R3=CONH2 
NH7 II R1= NO2; R2=H; R3=NHCH2CH(OH)CH2OH 
NH8 II R1= NO2; R2=H; R3=CONH(CH2)2Nmorpholide 
 569 
570 
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Table 2: Susceptibility of L. major and THP-1 cells to aziridinyl nitrobenzamidesa 571 
compounds group L. major IC50 (μM) differentiated 
THP-1 IC50 
(μM)c 
selective 
toxicityd  promastigotesb amastigotesc 
nifurtimox 
 
 7.50 ± 0.40 0.58 ± 0.06 >100 >172 
CB1954 Ia 0.42 ± 0.01 0.05 ± 0.02 >100 >2000 
NH1 Ia 7.32 ± 0.63 11.15 ± 2.01 >100 >9 
NH2 Ia 1.48 ± 0.18 2.95 ± 1.14 >100 >34 
NH9 Ia >10 0.67 ± 0.05 >100 >149 
NH10 Ia 0.49 ± 0.04 0.56 ± 0.05 >100 >178 
NH11 Ia 0.91 ± 0.07 0.06 ± 0.01 >100 >1667 
NH12 Ia >10 1.32 ± 0.02 >100 >76 
      
NH3-5 Ib >10 >10 nd nd 
      
NH6 II 6.85 ± 0.18 2.10 ± 0.22 >100 >48 
NH7-8 II >10 >10 nd nd 
 572 
and, not determined. bData are means from 4 experiments ± standard deviation. cData are 573 
means from 3 experiments ± standard deviation. dThe therapeutic index of a compound was 574 
calculated as a ratio of the IC50 against differentiated THP-1 cells to the IC50 against 575 
amastigote parasites. Nifurtimox was used as a reference compounds. 576 
 577 
Figure 1
Figure 1. Luciferase expression in insect- and mammalian-stage L. major. (A). The luciferase activity, in relative light units, of six
recombinant L. major promastigote clones (Luc1-6) was determined and compared to that of the parental line (wt). 1 x 106 cells were used in
each analysis. (B). L. major wild type (square; solid line) and LmNTR+/-BLA heterozygote (diamond; dotted line) promastigote parasites growth
was monitored until cultures were in the stationary phase of growth. From day 5 onward, the number of metacyclic form parasites in wild type
(triangle; solid line) and LmNTR+/-BLA heterozygote (triangle; dotted line) promastigote culture was determined following purification by
agglutination. The data is expressed as % metacyclics load in the total L. major population. All curves shown are derived from a single data set
and are representative of experiments performed in triplicate. (C). Purified L. major metacyclic parasites engineered to express luciferase were
d i f diff i d THP 1 ll O 4 d i f i i d d f h ll li d h l ifuse to n ect erent ate - ce s. ver a ay post n ect on per o , extracts were generate rom eac ce ne an t e uc erase
activity determined. Following background correction, the luciferase activity was plotted against time. All curves shown are derived from a
single data set and are representative of experiments performed in triplicate. (D). Correlation between promastigote load (between 625 to
160,000 cells) and luciferase activity. Three independent readings were taken for each parasite load and the values are means ± standard
deviation. (E). Correlation between luciferase activity and L. major amastigote load using various parasite/macrophage cell ratios (0:1 to 80:1).
Figure 2
Figure 2. Susceptibility of L. major to nifurtimox. Dose response curves of luciferase expressing L. major promastigotes (A) and amastigotes
(B) to nifurtimox were determined from which IC50 values were calculated. The data are the means from three independent experiments ±
standard deviation.
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Figure 3. Activity of LmNTR toward different aziridinyl nitrobenzamides. (A) SDS-PAGE gel (10 %) stained with Coomassie blue. Lane 1,
size standards; lane 2, purified HIS-tagged LmNTR. (B) The activity of purified recombinant LmNTR was assessed by using various ANBs as
substrates (100 μM) at a fixed concentration of NADH (100 μM). Enzyme activity, expressed in nmoles of NADH oxidised per minute per mg
LmNTR (nmol.mg-1min-1),, was then calculated using an ε value of 1,220 M-1 cm-1 with the assumption that four molecules of NADH are
o idised per molec le of ANB red ced (46) NFX (nif rtimo ) as sed as control For nif rtimo the change in absorbance at 435 nm asx u u . u x w u . u x, w
followed and enzyme activity determined using an ε value of 19,000 mM-1cm-1, again assuming that four molecules of NADH were oxidised per
molecule of nitrofuran reduced (47). The enzyme activity values are the means of data from three assays ± standard deviations. The ANB group
designations as listed in Table 1 are noted.
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ANBs were tested against L. major and THP-1 cells. The growth inhibitory effect of each treatment was evaluated and dose response curves
constructed for promastigotes (●), amastigotes (■) and differentiated THP-1 cells (▲). In all cases, drug treatments were performed in triplicate
and the plots shown represent the average growth inhibition obtained at each concentration ± standard deviation. The curves for compounds
CB1954, NH6 and NH10 are shown.
